R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles